ONE-WAYDated event · through FY2022-Q3
Start of Phase I clinical trial and discontinuation of development of the FPR2 agonist program
A standalone pharmaceutical development theme involving the FPR2 agonist program, under which Bristol Myers Squibb, the licensee, started a Phase I clinical trial, then discontinued development as a result of its development strategy, returning the development rights and other rights.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2018-Q3 →Last written FY2022-Q3
Directionhurts0 helps · 1 hurts · 0 flat